Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, Zepbound

Advertisement

Advertise with us

Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products.

Read this article for free:

or

Already have an account? Log in here »

To continue reading, please subscribe:

Monthly Digital Subscription

$0 for the first 4 weeks*

  • Enjoy unlimited reading on winnipegfreepress.com
  • Read the E-Edition, our digital replica newspaper
  • Access News Break, our award-winning app
  • Play interactive puzzles

*No charge for 4 weeks then price increases to the regular rate of $19.00 plus GST every four weeks. Offer available to new and qualified returning subscribers only. Cancel any time.

Monthly Digital Subscription

$4.75/week*

  • Enjoy unlimited reading on winnipegfreepress.com
  • Read the E-Edition, our digital replica newspaper
  • Access News Break, our award-winning app
  • Play interactive puzzles

*Billed as $19 plus GST every four weeks. Cancel any time.

To continue reading, please subscribe:

Add Free Press access to your Brandon Sun subscription for only an additional

$1 for the first 4 weeks*

  • Enjoy unlimited reading on winnipegfreepress.com
  • Read the E-Edition, our digital replica newspaper
  • Access News Break, our award-winning app
  • Play interactive puzzles
Start now

No thanks

*Your next subscription payment will increase by $1.00 and you will be charged $16.99 plus GST for four weeks. After four weeks, your payment will increase to $23.99 plus GST every four weeks.

Hey there, time traveller!
This article was published 05/12/2024 (365 days ago), so information in it may no longer be current.

Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products.

Lilly said Thursday it will expand a Kenosha County, Wisconsin, factory it bought early this year, and the investment will help meet growing demand for injectable products like its diabetes and obesity drugs, Mounjaro and Zepbound.

Those drugs brought in a combined $4.4 billion in sales for Lilly in this year’s third quarter.

David Ricks, chair and CEO of Eli Lilly, back right, announces the company's expansion in Wisconsin on Thursday, Dec. 5, 2024, in Kenosha, Wis. (Sean Krajacic/The Kenosha News via AP)
David Ricks, chair and CEO of Eli Lilly, back right, announces the company's expansion in Wisconsin on Thursday, Dec. 5, 2024, in Kenosha, Wis. (Sean Krajacic/The Kenosha News via AP)

The drugmaker plans to start construction of the expansion next year.

Lilly also announced other multibillion-dollar manufacturing expansion projects near its Indianapolis headquarters earlier this year.

Eli Lilly and Co. said Thursday that it has slated more than $23 billion to construct, expand or acquire manufacturing sites worldwide since 2020.

Report Error Submit a Tip